Clinical trials: Epithelial Tumors, Malignant
Primary Hepatocellular Carcinoma
29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
This clinical study plans to include 350 liver cancer patients from 10 tertiary hospitals nationwide, starting from August 1, 2025, at multiple centers such as the affiliated Run Run Shaw Hospital of Zhejiang University School of…
- Trial name
- NCT07100236
- Testing
- Observational study of 29 - gene - defined HCC subtypes and immunotherapy responsiveness correlation
- Where
- 13 sites in China
- Volunteers
- 350 people
- Sponsor
- Junjie Xu
Nasopharyngeal Carcinoma
IMRT Plus Cisplatin Versus IMRT in Patients With Stage 2 Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma has high incidence in the southern China, especially in Guangdong Province. In the world, the standardized morbidity has reached 30/10 million in men while in women, about 13/10 million.
- Trial name
- NCT03068936
- Testing
- Intensity modulated radiotherapy, Cisplatin
- Volunteers
- 716 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Advanced Hormone Dependent Prostate Cancer
Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina
Prospective, observational study to collect and analyze data on patients with advanced hormone dependent prostate cancer treated with Firmagon® according to routine medical practice in Argentina
- Trial name
- FAST AR (NCT01861236)
- Testing
- Firmagon® (degarelix)
- Where
- Argentina
- Volunteers
- 90 people
- Sponsor
- Ferring Pharmaceuticals
Esophageal Neoplasms
First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study
The purpose of this Chinese extension study is to evaluate efficacy and safety of pembrolizumab plus cisplatin and 5-fluorouracil (5-FU) chemotherapy versus placebo plus cisplatin and 5-FU chemotherapy as first-line treatment in…
- Trial name
- NCT03881111
- Testing
- Pembrolizumab, Cisplatin, 5-FU
- Where
- 20 sites in China
- Sponsor
- Merck Sharp & Dohme LLC
Hepatocellular Carcinoma
Impact of Propofol-Based Total Intravenous Anesthesia Versus Anesthesia With Sevoflurane on Long-term Outcomes With Patients Undergoing Elective Excision of Primary Liver Tumors
This is a two-arm, parallel-group randomized clinical trial. Routine perioperative care would be performed in volunteers with primary Hepatocellular carcinoma.
- Trial name
- NCT05331911
- Testing
- Propofol, Sevoflurane
- Where
- Taiwan
- Volunteers
- 500 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Any Stage of Lung Cancer (Any Histotype), Any Stage of Malignant Pleural Mesothelioma
SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access
SPECTAlung is a program aiming at screening patients with thoracic tumors to identify the molecular characteristics of their disease.
- Conditions
- Any Stage of Lung Cancer (Any Histotype), Any Stage of Malignant Pleural Mesothelioma, Any Stage of Any Thymic Malignancy
- Trial name
- SPECTAlung (NCT02214134)
- Testing
- Tumour markers testing
- Where
- 18 sites in Belgium, France and 7 more
- Volunteers
- 539 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
This phase I trial studies the side effects of vaccine therapy when given together with sargramostim in treating patients with malignant glioma.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Giant Cell Glioblastoma
- Trial name
- NCT01250470
- Testing
- Laboratory Biomarker Analysis, Montanide ISA-51/Survivin Peptide Vaccine, Sargramostim
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Roswell Park Cancer Institute
Non-small Cell Lung Cancer
Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer
This double-blind, randomized, placebo-controlled, multicenter, Phase III study is designed to evaluate the efficacy and safety of ensatinib compared with placebo as adjuvant treatment in ALK positive stage II-IIIB non-small cell…
- Trial name
- NCT05341583
- Testing
- Ensartinib
- Where
- China
- Volunteers
- 202 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Hepatocellular Carcinoma
HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, 5-fluorouracil and leucovorin plus sorafenib compared with HAIC of irinotecan, oxaliplatin…
- Trial name
- NCT03812783
- Testing
- Hepatic arterial infusion chemotherapy, Folfox Protocol, Sorafenib
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Estrogen Receptor Negative, HER2/Neu Negative
Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer
This phase I clinical trial studies the side effects and the best dose of dinaciclib when given together with epirubicin hydrochloride (epirubicin) in patients with metastatic (cancer that has spread to other parts of the body)…
- Conditions
- Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative
- Trial name
- NCT01624441
- Testing
- Dinaciclib, Epirubicin Hydrochloride, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Squamous Cell of Head and Neck
Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer
This trial aimed to assess efficacy and safety of cetuximab when given in combination with chemotherapy compared with chemotherapy alone in Chinese participants with recurrent and/or metastatic squamous cell carcinoma of the head…
- Trial name
- CHANGE2 (NCT02383966)
- Testing
- Cetuximab, Cisplatin/Carboplatin, 5-fluorouracil
- Where
- Germany
- Volunteers
- 243 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Nasopharyngeal Carcinoma, Neoplasm Metastasis
Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma
This single-center, open-label, randomized phase II trial evaluates whether CT-guided local ablation of liver and/or lung oligometastases, added to systemic therapy, improves the objective response rate compared with systemic…
- Conditions
- Nasopharyngeal Carcinoma, Neoplasm Metastasis, Lung Metastases, Liver Metastases
- Trial name
- NCT07824856
- Testing
- CT-guided percutaneous local ablation, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
The purpose of this study is to see if a three method risk adapted design using induction chemotherapy, transoral surgery and radiation chemotherapy will lessen toxic effects and make treatment of squamous cell carcinoma of the…
- Trial name
- NCT01612351
- Testing
- Carboplatin, Paclitaxel, Lapatinib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Ovarian Cancer
Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer
Phase IIA, multicenter, dose escalation study evaluating the safety and efficacy of weekly S-8184 paclitaxel injectable emulsion in second line treatment of patients with stage III or IV platinum resistant ovarian cancer or…
- Trial name
- NCT00034151
- Testing
- S-8184 Paclitaxel Injectable Emulsion
- Volunteers
- 52 people
- Sponsor
- Achieve Life Sciences
Non Small Cell Lung Cancer (NSCLC)
Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO
To assess the impact of prophylactic treatment on the incidence of adverse events in advanced NSCLC patients (post chemotherapy) treated with dacomitinib daily as a single agent.
- Trial name
- ARCHER 1042 (NCT01465802)
- Testing
- Dacomitinib, Doxycycline, Probiotic
- Where
- 81 sites in United States, South Korea
- Volunteers
- 236 people
- Sponsor
- Pfizer
Head and Neck Squamous Cell Carcinoma, Locally Advanced Stage
Molecular-Based Selection of Patients with Head and Neck Squamous Cell Carcinoma: Biomarker Analysis
This is an observational, prospective study enrolling patients who meet the inclusion criteria and provide consent for the use of biopsy samples collected as part of standard clinical practice.
- Trial name
- NCT06905145
- Testing
- Biomarkers evaluation
- Where
- Italy
- Volunteers
- 128 people
- Sponsor
- National Cancer Institute, Naples
Lung Cancer
Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Celecoxib may stop the growth of cancer by stopping blood flow to the tumor. Erlotinib and celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
- Trial name
- NCT00072072
- Testing
- celecoxib, erlotinib hydrochloride
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma
Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer
This phase I trial tests the safety, side effects, and best dose of tazemetostat in combination with topotecan and pembrolizumab in treating patients with small cell lung cancer that has come back after a period of improvement…
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma
- Trial name
- NCT05353439
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 15 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Cancer of the Liver
Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract
To evaluate objective response rate and duration of response to weekly Taxoprexin®. To evaluate the safety profile of weekly Taxoprexin® in this patient population. To evaluate overall survival in the same patient population.
- Trial name
- NCT00422877
- Testing
- Taxoprexin
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- American Regent, Inc.
Locally Advanced Non-Small Cell Lung Cancer, NSCLC
Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy
A phase II study of combination therapy of carboplatin -gemcitabine plus bevacizumab beyond progression in patients with locally advanced and/or metastatic non-small cell lung cancer (NSCLC) who have not received prior…
- Trial name
- NCT00702975
- Testing
- Paclitaxel, Carboplatin and Bevacizumab,Erlotinib
- Where
- Netherlands
- Volunteers
- 35 people
- Sponsor
- Radboud University Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.